This article and associated images are based on a poster presented at ELRIG Drug Discovery 2025 in affiliation with PartitionBio.
This poster is being hosted on this website in its raw form, without modifications. It has not undergone peer review but has been reviewed to meet AZoNetwork's editorial quality standards. The information contained is for informational purposes only and should not be considered validated by independent peer assessment.
- Room‑temperature stability
- Low cytotoxicity
- Supercharged performance
- Non‑viral, highly biocompatible
- Gentle on sensitive cells
Smarter cell delivery
54 % transfected area. Image Credit: PartitionBio
39 % transfected area. Image Credit: PartitionBio
Delivering antibodies inside cells
- Unlocks new frontiers in research and therapeutics.
Cargo: Intracellular targeting antibody
Image Credit: PartitionBio
Image Credit: PartitionBio
About PartitionBio
Optimized for High-Throughput Screening
Image Credit: PartitionBio
CRISPR-Ready with Low Toxicity & High Consistency
Image Credit: PartitionBio
Powerful in Functional Genomics Workflows
Image Credit: PartitionBio
- Protein and Enzyme Replacement Therapies
- Advanced Research Tools and Cell Engineering
- Nucleic Acid Delivery
About PartitionBio
PartitionBio is a UK-based biotech company developing next-generation drug delivery systems using biomolecular condensates formed through liquid-liquid phase separation (LLPS). Their non-viral platform enables efficient delivery of macromolecules like nucleic acids and proteins into human cells, aiming to improve therapeutic outcomes. PartitionBio is advancing accessible solutions for global health.
About ELRIG (UK) Ltd.
The European Laboratory Research & Innovation Group (ELRIG) is a leading European not-for-profit organization that exists to provide outstanding scientific content to the life science community. The foundation of the organization is based on the use and application of automation, robotics, and instrumentation in life science laboratories, but over time, we have evolved to respond to the needs of biopharma by developing scientific programmes that focus on cutting-edge research areas that have the potential to revolutionize drug discovery.
Comprised of a global community of over 12,000 life science professionals, participating in our events, whether it be at one of our scientific conferences or one of our networking meetings, will enable any of our community to exchange information, within disciplines and across academic and biopharmaceutical organizations, on an open access basis, as all our events are free of charge to attend!
Our values
Our values are always to ensure the highest quality of content, that content will be made readily accessible to all, and that we will always be an inclusive organization, serving a diverse scientific network. In addition, ELRIG will always be a volunteer-led organization, run by and for the life sciences community, on a not-for-profit basis.
Our purpose
ELRIG is a company whose purpose is to bring the life science and drug discovery communities together to learn, share, connect, innovate, and collaborate on an open-access basis. We achieve this through the provision of world-class conferences, networking events, webinars, and digital content.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.
Last Updated: Nov 26, 2025